Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart

NCT01782300 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

NIH

Sponsor class

Conditions

Dengue

Interventions

BIOLOGICAL: TV003 Vaccine
BIOLOGICAL: Placebo Vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)